Topic: restructuring

The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.

Compugen is “streamlining” its R&D operations to pare down costs and ensure it can afford the phase 1 study of its lead asset, an anti-PVRIG antibody.

The major restructuring is intended to keep Merrimack operating and raking in milestones from Ipsen while it looks into strategic alternatives.

The latest restructuring is intended to slash up to 40% of Achaogen’s expenses, enabling the antibiotic company to hunker down and search for an exit.

Bayer is contemplating outsourcing more of its R&D as part of an overall restructuring plan, Reuters says.

Momenta is axing 50% of its workforce as it drops the bulk of its biosimilar work in favor of an immunology-based novel pipeline.

The reshuffle comes as Novo seeks to build a pipeline of chronic disease drugs capable of mitigating the pressures faced by its diabetes business.

A management review at Bayer could result in job cuts and outsourcing the company’s drug-testing services, according to Reuters.

NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing.

The impact of Achaogen’s narrower-than-expected label for Zemdri is now apparent: The biotech has cut 28% of its staff and all but two R&D programs.